Member Info for JimiHendrix

Thanks JLC. Stocksaint, please enlighten us as to which parts of my posts are in your opinion blatant lies?

Also, no actually I’ve made considerable profits here.

Stocksaint, you may be misunderstanding. Genedrive are not waiting for NICE clearances before they can sell AIHL — they can and indeed are selling now. Any hospital or clinic in the UK can install and use the test now. NICE evidence generation is about long term recommendation, as they have already given final approval and recommendation for the NHS to use the test now, through the early access scheme.

AIHL was launched in Austria last week. I would think any necessary approvals required to sell in Austria must have been received previously otherwise launching the test would surely be a bit premature. Hopefully an RNS to clarify this week.

We should hear about this funding too soon, I would think. Anybody have any thoughts about this?

“The technology developer is responsible for ensuring that data collection and data analysis takes place. Support for evidence generation will be available through a competitive process facilitated by the Office for Life Sciences, pending business case approval. This will be in the form of funding for evidence generation consortia, bringing analytical partners and implementation sites together with developers for evidence generation.

Guidance on commissioning and procurement of the technology will be provided by NHS England. NHS England is developing a digital health technology policy framework which will further outline commissioning pathways.“

Rewritten so it makes sense lol…

Yes but the money given to the projects will be used to fund the development costs (as well as implementation etc), ie paying the company who is developing it (Genedrive). So whilst the funding doesn’t come directly to the company, it’s still coming to the company via paying for the company’s work/services.

Yes but the money given to the projects will be among st other things used to fund the development costs, ie paying the company who is developing it (Genedrive). So whilst the funding doesn’t come directly to the coming, it’s still coming to the company via paying for the company’s work/services.

Yes indeed. We might even get an RNS next week, as this was only posted an hour ago.

Genedrive launched in Austria…

“Great week in Austria supporting genedrive and long time friends Andrea Calvin Connect Medizintechnik GmbH with Patrick Breen and Joanne Inglis Launching Genedrive in Austria. Visiting @LKH Salzberg. #innovationinhealthcare #TransformMedTechConsultancy”

Some technicians do have decision making responsibilities actually. And for any that don’t, well their opinions and feedback will have great influence on the decision makers. it is essential that Genedrive attends these events to show off the products.

Licensing deal or takeover would make a lot of sense, the latter very likely at some point given the chairman’s history.

Roger, RF will already have sold the initial 6.5m as per the terms of the facility, a requirement before they could request new shares for any shortfall.

Sorry I’ve just noticed Mum has posted the very same snippet. Anyway, yes Gloria, this is all looking very exciting and things are very much moving forward.

The huge buys today say everything really.

Sounds like more funding will come via the Office for Life Sciences.

It makes it very clear that the NHS will be using the test while data is gathered, and the test will be implemented across the country…

…

“NICE's assessment of the Genedrive MT-RNR1 ID Kit recommends that further evidence is generated while it is being used in the NHS.

This plan outlines the evidence gaps for the technology and what real-world data needs to be collected for a NICE review of the technology again in the future. It is not a study protocol.

The technology developer is responsible for ensuring that data collection and data analysis takes place. Support for evidence generation will be available through a competitive process facilitated by the Office for Life Sciences, pending business case approval. This will be in the form of funding for evidence generation consortia, bringing analytical partners and implementation sites together with developers for evidence generation.

Guidance on commissioning and procurement of the technology will be provided by NHS England. NHS England is developing a digital health technology policy framework which will further outline commissioning pathways.“

..,

“Use in a wide range of geographical regions

Implementing the Genedrive MT-RNR1 ID Kit in a wide range of geographical regions would support babies from different socioeconomic groups having access to the test. It would also generate evidence for services with differences in practice.”

I’ve been giving the NICE update a thorough read this evening, it’s great news actually. Some interesting bits…

“Support for evidence generation will be available through a competitive process facilitated by the Office for Life Sciences, pending business case approval. This will be in the form of funding for evidence generation consortia, bringing analytical partners and implementation sites together with developers for evidence generation.”

I expect Roger and Stars are now fully loaded lol.

I’m expecting similar funding grants to become available for other regions across the country.

Exactly Gloria! Lol, there’s nothing new in the update. It’s great timing for the derampers though allowing them to panic a few in to selling and the market makers happy to drop it briefly to pick up the volume. Still very difficult to buy in quantity.

I noticed earlier a £30k sell at around 12 and then moments later when buying picked up 2 large odd amounts of shares were purchased at a premium 13.4 amounting to £30k… wouldn’t surprise me if that was the same person realising it’s better to be in at these price levels.

Some people are probably forgetting that the NHS is behind the development of the AIHL test. It will be adopted routinely, and by the time the data collection period is up it will already be everywhere.

Data collection will be funded as part of the grant money. There’s nothing shocking in the NICE update, let the rollout continue.

Opportunity for a bargain too up now though!

They’ve stopped working on it because it’s finished, Roger. They’re not trying to sell it because there’s no demand for it. However as per the RNSs and meetings, they are ready if there was to be a new outbreak and if there was demand in the future.

I can’t believe these greedy derampers, the levels they go to to try to subtlety encourage people to sell so that they can buy in slightly cheaper, with no consideration of those who may miss out as a result of selling.

Very interesting, thanks for posting. Diagnostics and bio markers mentioned too…

…

Domestic examples of DTV initiatives

The UK supports efforts to provide timely, safe and effective DTVs within 100 days through strengthening domestic capabilities, global contributions, partnerships and investments in research and development.

This includes successful contributions to the development and evaluation of DTVs for a range of pathogens through ongoing research and collaboration with global partners and support for product development partnerships (PDPs).

Funding initiatives such as the Health Technology Regulatory and Innovation Programme, a £7 million fund to help UK HealthTech small and medium enterprises (SMEs) with regulation. The fund is a joint initiative between UK Research and Innovation (UKRI) and the Association of British HealthTech Industries (ABHI).

There are over £500 million private sector investments, including expansion at:

Fujifilm Diosynth Biotechnologies (Billingham)

ThermoFisher Scientific (Swindon)

Wockhardt (Wrexham)

Oxford Biomedical (Harwell)

UKHSA’s creation of its own Vaccine Development and Evaluation Centre (VDEC) to support the development and laboratory (in vivo and in vitro) evaluation of new vaccines and vaccine technologies is part of pandemic preparedness efforts. VDEC secures the legacy from the COVID-19 pandemic and brings together UKHSA’s laboratory-based activity, expertise and leadership in vaccine discovery, development and evaluation, as well as applying UKHSA’s expertise in partnership with industry and academia.

UKHSA is also continuing work to identify diagnostic requirements for each pathogen group and advancing diagnostic development activity. To minimise duplication and ensure a consistent approach, UKHSA is engaging with organisations such as the Foundation for Innovative Diagnostics (FIND) and the Bill and Melinda Gates Foundation (BMGF).

Industry and academia are essential to the UK’s ability to explore and develop DTVs. The UK government actively supports programmes to maintain working partnerships with the pharmaceutical industry, university research bodies and health protection research bodies, allowing DTVs to be explored pre-emptively and proactively during non-emergency times and made available rapidly during a pandemic.

For example, the UK’s 10-year strategic partnership with Moderna was announced in December 2022. The 3 connected strands of the deal cover:

the building of a UK manufacturing facility, biomarker laboratory and supply of mRNA vaccines to the UK

substantial investment in mRNA research and development

the capability to scale up and respond in the event of a future pandemic

The data gathering for NICE is for long term recommendation and continued use, this doesn’t stop the test being rolled out nationally now. As I’ve said it’s a gradual rollout, starting in the north west not instant… it will take time. I expect by the time the data is gathered, the test may already be in full use in most areas.

The whole point of early adoption is to allow the test to be used whilst further data is gathered over a longer period of time. Also remember that the test saves NHS money, it’s not an additional cost.